appendix e handling and shipping
references

1.Simon R. Optimal two-stage designs for phase II clinical trials. Controlled Clinical Trials 1989;10:1-10. 2.Common terminology criteria for adverse events v4.0. 2009. (Accessed September 14, 2010, at http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf.) 3.Durie BGM, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia 2006;20:1467-73. 4.Björkstrand B, Gahrton G. High-Dose Treatment With Autologous Stem Cell Transplantation in Multiple Myeloma: Past, Present, and Future. Seminars in Hematology 2007;44:227-33. 5.Attal M, Harousseau J-L, Stoppa A-M, et al. A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma. New England Journal of Medicine 1996;335:91-7. 6.Moreau P, Facon T, Attal M, et al. Comparison of 200 mg/m2 melphalan and 8 Gy total body irradiation plus 140 mg/m2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myélome 9502 randomized trial. Blood 2002;99:731-5. 7.Harousseau J-L, Attal M, Avet-Loiseau H, et al. Bortezomib Plus Dexamethasone Is Superior to Vincristine Plus Doxorubicin Plus Dexamethasone As Induction Treatment Prior to Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: Results of the IFM 2005-01 Phase III Trial. Journal of Clinical Oncology 2010;28:4621-9. 8.Roussel M, Moreau P, Huynh A, et al. Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myélome (IFM). Blood 2010;115:32-7. 9.Chanan-Khan AA, Giralt S. Importance of Achieving a Complete Response in Multiple Myeloma, and the Impact of Novel Agents. Journal of Clinical Oncology 2010;28:2612-24. 10. Otsuka Pharmaceutical Co L. Product Monograph for Busulfex (busulfan) 6mg/ml injection. May 2008. In; May 2008. 11.Bhagwatwar H, Phadungpojna S, Chow D, Andersson B. Formulation and stability of busulfan for intravenous administration in high-dose chemotherapy. Cancer Chemotherapy and Pharmacology 1996;37:401-8. 12.IV Busulfex (Busulfan) Investigator's Brochure. Edition 1. In; Version March 18, 2009. 13.Madden T, de Lima M, Thapar N, et al. Pharmacokinetics of Once-Daily IV Busulfan as Part of Pretransplantation Preparative Regimens: A Comparison with an Every 6-Hour Dosing Schedule. Biology of Blood and Marrow Transplantation 2007;13:56-64.  
14.Andersson BS, Thall PF, Madden T, et al. Busulfan systemic exposure relative to regimenrelated toxicity and acute graft-versus-host disease: Defining a therapeutic window for i.v.  
BuCy2 in chronic myelogenous leukemia. Biology of Blood and Marrow Transplantation 2002;8:477-85.  
15.Aggarwal C, Gupta S, Vaughan WP, et al. Improved Outcomes in Intermediate- and HighRisk Aggressive Non-Hodgkin Lymphoma after Autologous Hematopoietic Stem Cell Transplantation Substituting Intravenous for Oral Busulfan in a Busulfan, Cyclophosphamide, and Etoposide Preparative Regimen. Biology of Blood and Marrow Transplantation 2006;12:770-7. 16.Kletzel M, Jacobsohn D, Duerst R. Pharmacokinetics of a Test Dose of Intravenous Busulfan Guide Dose Modifications to Achieve an Optimal Area Under the Curve of a Single Daily Dose of Intravenous Busulfan in Children Undergoing a Reduced-Intensity Conditioning Regimen  
  
with Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation 2006;12:472-9. 17.Fernandez HF, Tran HT, Albrecht F, Lennon S, Caldera H, Goodman MS. Evaluation of safety and pharmacokinetics of administering intravenous busulfan in a twice-daily or daily schedule to patients with advanced hematologic malignant disease undergoing stem cell transplantation. Biology of Blood and Marrow Transplantation 2002;8:486-92. 18.Mamlouk K, Saracino G, Berryman RB, et al. Modification of the Bu//Cy myeloablative regimen using daily parenteral busulfan: reduced toxicity without the need for pharmacokinetic monitoring. Bone Marrow Transplant 2005;35:747-54. 19.Ryu S-G, Lee J-H, Choi S-J, et al. Randomized Comparison of Four-Times-Daily versus Once-Daily Intravenous Busulfan in Conditioning Therapy for Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation 2007;13:1095-105. 20.Santos EC, Sessions J, Hutcherson D, Flowers C, Langston A, Waller EK. Long-term Outcome of Hodgkin Disease Patients Following High-Dose Busulfan, Etoposide, Cyclophosphamide, and Autologous Stem Cell Transplantation--A Similar Experience. Biology of Blood and Marrow Transplantation 2007;13:746-7. 21.Wadehra N, Farag S, Bolwell B, et al. Long-term Outcome of Hodgkin Disease Patients Following High-Dose Busulfan, Etoposide, Cyclophosphamide, and Autologous Stem Cell Transplantation. Biology of Blood and Marrow Transplantation 2006;12:1343-9. 22.Blanes M, de la Rubia J, Lahuerta JJ, et al. Single daily dose of intravenous busulfan and melphalan as a conditioning regimen for patients with multiple myeloma undergoing autologous stem cell transplantation: a phase II trial. Leukemia & Lymphoma 2009;50:216-22. 23.Kebriaei P, Madden T, Kazerooni R, et al. Intravenous Busulfan Plus Melphalan Is a Highly Effective, Non-Toxic Preparative Regimen for Autologous Stem Cell Transplantation (ASCT) in Patients with Advanced Lymphoid Malignancies. ASH Annual Meeting Abstracts 2009;114:3415-. 24.Blanes M, De La Rubia J, Lahuerta J-J, et al. Outcomes In Patients with Multiple Myeloma Following Autologous Stem Cell Transplantation Using Intravenous Busulfan and Melphalan: A Matched Comparison to a Double Autologous Transplant Strategy. ASH Annual Meeting Abstracts 2010;116:3560-. 25.Nieto Y, Vaughan WP. Pharmacokinetics of high-dose chemotherapy. Bone Marrow Transplant 2003;33:259-69. 26.Millennium Pharmaceuticals I. Velcade Prescribing Information. In; December 2006. 27.Richardson PG, Barlogie B, Berenson J, et al. A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma. New England Journal of Medicine 2003;348:2609-17. 28.Strauss SJ, Maharaj L, Hoare S, et al. Bortezomib Therapy in Patients With Relapsed or Refractory Lymphoma: Potential Correlation of In Vitro Sensitivity and Tumor Necrosis Factor Alpha Response With Clinical Activity. Journal of Clinical Oncology 2006;24:2105-12. 29. Almond Jb Fau - Cohen GM, GM C. - The proteasome: a novel target for cancer chemotherapy. Leukemia 2002;16:433-43. 30.Cusack JC, Liu R, Houston M, et al. Enhanced Chemosensitivity to CPT-11 with Proteasome Inhibitor PS-341. Cancer Research 2001;61:3535-40. 31.Ling Y-H, Liebes L, Zou Y, Perez-Soler R. Reactive Oxygen Species Generation and Mitochondrial Dysfunction in the Apoptotic Response to Bortezomib, a Novel Proteasome Inhibitor, in Human H460 Non-small Cell Lung Cancer Cells. Journal of Biological Chemistry 2003;278:33714-23. 32.Marks PA, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK. Histone deacetylases  
  
and cancer: causes and therapies. Nat Rev Cancer 2001;1:194-202. 33.An B Fau - Goldfarb RH, Goldfarb Rh Fau - Siman R, Siman R Fau - Dou QP, QP D. - Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts. Cell Death Differ 1998;5:1062-75. 34.Harousseau J-L, Palumbo A, Richardson PG, et al. Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone. Blood 2010;116:3743-50. 35.Richardson PG, Mitsiades C, Schlossman R, Munshi N, Anderson K. New Drugs for Myeloma. Oncologist 2007;12:664-89. 36.Rodriguez TE, Stiff PJ, Smith SE, et al. High Dose Intravenous Busulfan (BU) and Melphalan (MEL) Followed by Bortezomib (BTZ) as Conditioning with Autologous Peripheral Blood Stem Cell Transplantation (ASCT) for Patients with Multiple Myeloma (MM). ASH Annual Meeting Abstracts 2010;116:1355-. 37.Dean RM, Pohlman B, Sweetenham JW, et al. Superior survival after replacing oral with intravenous busulfan in autologous stem cell transplantation for non-Hodgkin lymphoma with busulfan, cyclophosphamide and etoposide. Br J Haematol 2010;148:226-34. 38.Toman I, Loree J, Klimowicz AC, et al. Expression and prognostic significance of Oct2 and Bob1 in multiple myeloma: implications for targeted therapeutics. Leukemia & Lymphoma 2011;52:659-67. 39.Hervé A-L, Florence M, Philippe M, et al. Molecular Heterogeneity of Multiple Myeloma: Pathogenesis, Prognosis, and Therapeutic Implications. Journal of Clinical Oncology 2011;29:1893-7. 40.Sawyer JR. The prognostic significance of cytogenetics and molecular profiling in multiple myeloma. Cancer Genetics 2011;204:3-12. 41.Munshi NC, Anderson KC, Bergsagel PL, et al. Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. Blood 2011;117:4696-700. 42.Nair B, van Rhee F, Shaughnessy JD, et al. Superior results of Total Therapy 3 (2003-33) in gene expression profiling–defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance. Blood 2010;115:4168-73. 43.Burington B, Barlogie B, Zhan F, Crowley J, Shaughnessy JD. Tumor Cell Gene Expression Changes Following Short-term In vivo Exposure to Single Agent Chemotherapeutics are Related to Survival in Multiple Myeloma. Clinical Cancer Research 2008;14:4821-9. 44.Shaughnessy JD, Qu P, Usmani S, et al. Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with total therapy 3. Blood 2011. 45.Oda M, Glass JL, Thompson RF, et al. High-resolution genome-wide cytosine methylation profiling with simultaneous copy number analysis and optimization for limited cell numbers. Nucleic Acids Res 2009. 46. Oda M, Greally JM. The HELP assay. Methods Mol Biol 2009;507:77-87. 47.Heuck CJ, Mehta J, Tariman J, et al. Epigenomic Profiling of Multiple Myeloma Shows Widespread Stage Specific Alterations In DNA Methylation That Occur Early During Myelomagenesis. Blood 2010;116: Abstract 784. 48.Sharma A, Heuck CJ, Fazzari MJ, et al. DNA methylation alterations in multiple myeloma as a model for epigenetic changes in cancer. Wiley Interdiscip Rev Syst Biol Med 2009;2:654-69.  
61  
  
49. Rajkumar SV. Multiple myeloma: 2011 update on diagnosis, risk-stratification, and management. American Journal of Hematology 2011;86:57-65. 50.Attal M, Cristini C, Marit G, et al. Lenalidomide maintenance after transplantation for myeloma. ASCO Meeting Abstracts 2010;28:8018. 51.McCarthy PL, Owzar K, Anderson KC, et al. Phase III intergroup study of lenalidomide versus placebo maintenance therapy following single autologous stem cell transplant (ASCT) for multiple myeloma (MM): CALGB 100104. ASCO Meeting Abstracts 2010;28:8017. 52.Cavo M, Rajkumar SV, Palumbo A, et al. International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. Blood 2011;117:6063-73. 53. Greipp PR, Miguel JS, Durie BGM, et al. International Staging System for Multiple Myeloma. Journal of Clinical Oncology 2005;23:3412-20. 54.Jones Rj Fau - Lee KS, Lee Ks Fau - Beschorner WE, Beschorner We Fau - Vogel VG, et al. - Venoocclusive disease of the liver following bone marrow transplantation. Transplantation 1987;44:778-83. 55.McDonald GB, Hinds MS, Fisher LD, et al. Veno-occlusive Disease of the Liver and Multiorgan Failure after Bone Marrow Transplantation: A Cohort Study of 355 Patients. Annals of Internal Medicine 1993;118:255-67. 56.Weaver Ch Fau - Schwartzberg LS, Schwartzberg Ls Fau - Hainsworth J, Hainsworth J Fau - Greco FA, et al. - Treatment-related mortality in 1000 consecutive patients receiving high-dose chemotherapy and peripheral blood progenitor cell transplantation in community cancer centers. Bone Marrow Transplant 1997;19:671-8. 57.Rosiñol L, Pérez-Simón JA, Sureda A, et al. A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma. Blood 2008;112:3591-3.